Genesis Bioventures Announces Change in Board of Directors

Genesis Bioventures, Inc. (GBI) (OTCBB:GBIW) today announced that the Company accepted the resignation of Mr. Antony S. Dyakowski, one of its former directors. Under the resignation terms and conditions agreed to by the Mr. Dyakowski and the Company the resignation became effective June 6, 2007. "I would like to thank Mr. Dyakowski on behalf of the Company for his past contributions,” Said Mr. Lane, Chairman and Chief Executive Officer. "We want to wish him the very best in his future professional endeavors.” About Genesis Bioventures, Inc. Genesis Bioventures, Inc. is a biomedical company focusing on the development and commercialization of its owned and licensed assets for diagnostic and therapeutic product development. Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.